Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Abstract

These findings describe solanezumab effects on efficacy/safety measures in a mild AD population. Another phase 3 study, EXPEDITION3, will investigate solanezumab's effects in a mild AD population.